Ani Pharmaceuticals Inc. (ANIP)
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E
ANI Pharmaceuticals ANIP has shifted into a specialty-led growth story, with Cortrophin Gel now the main engine and the retina franchise positioned for a reset and recovery. At the same time, the stock's valuation has compressed to levels that stand out against peers and the broader market.
ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset
ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts See a 44.84% Upside in ANI (ANIP): Can the Stock Really Move This High?
The mean of analysts' price targets for ANI (ANIP) points to a 44.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge
ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. I see near-term risks from seasonally weaker Cortrophin sales due to insurance reverifications and delayed impact from the expanded gout sales force. Management reaffirmed 2026 guidance for $1.06-$1.12B revenue and up to $290M adjusted EBITDA, but execution and timing risks remain.
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI (ANIP) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.63 per share a year ago.
Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?
ANIP gears up for Q4 earnings as Cortrophin Gel sales are expected to have surged, with rare disease momentum building despite generic competition pressures.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
